Diltiazem increases blood concentrations of cyclized cyclosporine metabolites resulting in different cyclosporine metabolite patterns in stable male and female renal allograft recipients

British Journal of Clinical Pharmacology

Volumn 41, Issue 6, 1996, Pages 551-556

  Bleck, J S ^a   Thiesemann, C ^a   Kliem, V ^a   Christians, U ^a   Hecker, H ^a   Repp, H ^a   Frei, U ^a   Westhoff Bleck, M ^a   Manns, M ^a   Sewing, K F ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

cyclosporine; diltiazem; drug interactions; metabolism; pharmacokinetics; renal allograft recipients

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450; DILTIAZEM; DRUG METABOLITE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 8944233363     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.34412.x     Document Type: Article

References (38)

1. Schachter M. Cyclosporine A and hypertension. J Hypertension 1988; 6: 511-516.
2. Frei U, Margreiter R, Harms A, et al. Preoperative graft reperfusion with a calcium antagonist improves initial function: preliminary results of a prospective randomized trial in 110 kidney recipients. Transplant Proc 1987; 19: 3539-3541.
3. Wagner K, Albrecht S, Neumeyer HH. Prevention of posttransplant acute tubular necrosis by the calcium antagonist diltiazem: a prospective randomized study. Am J Nephrol 1987; 7: 287-291.
4. Neumayer HH, Kunzendorf U, Schreiber M. Protective effects of diltiazem and the prostacyclin analogue iloprost in human renal transplantation. Renal Failure 1992; 14: 289-296.
5. Choy BY, Walker RG, Becker GJ. Vasculopathy in cyclosporine-treated renal allografts: possible protection by diltiazem. Clin Transplant 1994; 8: 271-273.
6. Carrier M, Tronc F, Stewart D, Pelletier LC. Dose-dependent effect of cyclosporin on renal arterial resistance in dogs. Am J Physiol 1991; 261: H1791-1796.
7. Dumont L, Chen H, Daloze P, Xu D, Garceau D. Immunosuppressive properties of the benzothiazepine calcium antagonists diltiazem and clentiazem, with and without cyclosporine, in heterotopic rat heart transplantation. Transplantation 1993; 56: 181-184.
8. Kudoh S, Satoh A. Basic studies on the prevention of cyclosporin A induced nephrotoxicity. Nippon Hinyokika Gakkai Zasshi 1994; 85: 768-777.
9. Chrysostomou A, Walker RG, Russ GR, d'Apice AJ, Kincaid-Smith P, Mathew TH. Diltiazem in renal allograft recipients receiving cyclosporine. Transplantation 1993; 55: 300-304.
10. Patton PR, Brunson ME, Pfaff WW, et al. A preliminary report of diltiazem and ketoconazole. Their cyclosporine-sparing effect and impact on transplant outcome. Transplantation 1994; 57: 889-899.
11. Valantine H, Keogh A. McIntosh N, Hunt S, Oyer P, Schroeder J. Cost containment: coadministration of diltiazem with cyclosporine after heart transplantation. J Heart Lung Transplant 1992 : 11: 1-8.
12. Richard L, Gillet G, Fabre I, et al. Identification of the rabbit and human cytochrome P450IIIA as the major enzymes in the N-demethylation of diltiazem. Drug Metab Dispos 1990; 18: 711-719.
13. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988; 43: 630-635.
14. Combalbert J, Fabre I, Fabre G, et al. Metabolism of cyclosporin A: IV. Purification and identification of the rifampicin inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989; 17: 197-207.
15. Christians U, Sewing KF. Cyclosporin metabolism in transplant patients. Pharmac Ther 1993; 57: 291-345.
16. Pichard L, Fabre I, Fabre G, et al. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990; 18: 595-606.
17. Kohlhaw K, Wonigeit K, Frei U, et al. Effect of the calcium channel blocker diltiazem on cyclosporine A blood levels and dose requirements. Transplant Proc 1988, 20: 572-574.
18. Kelly JJ, Walker RG, d'Apice AJF, Kincaid-Smith P. A prospective study of the effect of diltiazem in renal allograft recipients receiving cyclosporine A: preliminary results. Transplant Proc 1990; 22: 2127-2128.
19. McCauley J, Ptachcinski RJ, Shapiro R. The cyclosporine-sparing effect of diltiazem in renal transplantation. Transplant Proc 1989; 21: 3955-3957.
20. Kunzendorf U, Walz G, Brockmöller J, et al. Effects of diltiazem upon metabolism and immunosuppressive action of cyclosporine in kidney graft recipients. Transplantation 1991; 52: 280-284.
21. Christians U, Zimmer KO, Wonigeit K, Maurer G, Sewing KF. Liquid-chromatographic measurement of cyclosporin and its metabolites in blood, bile and urine. Clin Chem 1988; 34: 34-39.
22. Christians U, Strohmeyer S, Kownatzki R. et al. Investigations on the metabolic pathways of cyclosporine: I. Excretion of cyclosporine and its metabolites in human bile-isolation of 12 new cyclosporine metabolites. Xenobiotica 1991, 21: 1185-1198.
23. Consensus Document. Hawk's Cay meeting on the therapeutic drug monitoring of cyclosporine. Transplant Proc 1990; 22: 1357-1361.
24. Hecker H. Identification and interpretation of effects in two-period crossover designs. EDP in Medicine and Biology 1986; 17: 60-66.
25. Webber JR, Peters WHM, Back DJ. Cyclosporin metabolism by human gastrointestinal mucosal microsomes. J Clin Pharmacol 1992; 33: 661-664.
26. Kolars JC, Stetson PL, Rush BD, et al. Cyclosporin A metabolism by P450IIIA in rat enterocytes-another determinant of oral bioavailability? Transplantation 1992; 53: 596-602.
27. Kolars JC, Awni WM, Merion RM, Watkins PB. Firstpass metabolism of cyclosporin by the gut. Lancet 1991; 338: 1488-1490.
28. Hebert MF, Roberts JP, Prueksaritanont T, Benet L. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992; 52: 453-457.
29. Maurer G, Loosli HR, Schreier E, Keller B. Disposition of cyclosporine in several animal species and man. I. Structural elucidation of its metabolites. Drugs Metab Dispos 1984; 12: 120-126.
30. Hashem H, Venkataramana R, Burckart GJ, et al. Identification of the aldehydic metabolites. Transplant Proc 1988; 20: 176-178.
31. Sewing KF, Christians U, Kohlhaw K, et al. Biologic activity of cyclosporine metabolites Transplant Proc 1990; 22: 1129-1134.
32. th International Symposium on Microsomes and Drug Oxidation. Stockhom, Sweden, 1990; 218.
33. Prueksaritanont T, Correia MA, Rettie AE, Swinney DC, Thomas PE, Benet LZ. Cyclosporine metabolism by rat liver microsomes. Evidence for involvement of enzyme(s) other than cytochrome P450IIIA. Drug Metab Dis 1993; 21: 730-737.
34. Lucey MR, Kolars JC, Merion RM, Campbell DA, Aldrich M, Watkins PB. Cyclosporin toxicity at therapeutic blood levels and cytochrome P450 IIIA. Lancet 1990; 335: 11-15.
35. Copeland KR, Yatscoff RW. Comparison of the effects of cyclosporine and its metabolites on the release of prostacyclin and endothelin from mesangial cells. Transplantation 1992; 53: 640-645.
36. Hunt CM, Westerham WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992; 44: 275-283.
37. First MR, Schroeder TJ, Alexander WJ. Cyclosporine dose reduction by ketoconazole administration in renal transplant patients. Transplantation 1991; 51: 356-370.
38. Butman SJ, Wild JC, Nolan PE, et al. Prospective study of the safety and financial benefit of ketoconazole as adjunctive therapy to cyclosporine after heart transplantation. J Heart Lung Transplant 1991; 10: 351-358.